<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679146</url>
  </required_header>
  <id_info>
    <org_study_id>KETOP_R_02693</org_study_id>
    <nct_id>NCT00679146</nct_id>
  </id_info>
  <brief_title>Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain</brief_title>
  <acronym>TIOKET</acronym>
  <official_title>Efficacy and Safety of a Fixed Combination (Thiocolchicoside 8 mg + Ketoprofen 100 mg ) Compared to Thiocolchicoside 8 mg Administered Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective :&#xD;
&#xD;
      To demonstrate the superiority of the oral fixed - combination of a muscle relaxant,&#xD;
      thiocolchicoside (TCC) to a non steroidal anti-inflammatory drug, ketoprofen, over oral TCC,&#xD;
      on average pain within the last 24 hours in adults suffering from acute non specific low back&#xD;
      pain with an episode of recent onset&#xD;
&#xD;
      Secondary Objective :&#xD;
&#xD;
      To compare the safety of the oral combination to that of oral TCC alone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average pain within the last 24 hours (VAS)</measure>
    <time_frame>at D3 visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average pain within the last 24 hours (VAS)</measure>
    <time_frame>at D7 visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiocolchicoside+Ketoprofen</intervention_name>
    <description>1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiocolchicoside</intervention_name>
    <description>2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        List of Inclusion and Exclusion criteria :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Non specific low back pain with an acute episode of recent onset (&lt;48 hours) defined&#xD;
             by average pain within the last 24 hours equal or more than 50 mm on the Visual&#xD;
             Analogue Scale (VAS)&#xD;
&#xD;
          -  Low back pain of diagnosis category 1 (low back pain radiating no farther than the&#xD;
             intergluteal fold) or 2 (low back pain radiating no farther than the knee), as defined&#xD;
             by the International Paris Task Force on Back Pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria related to study methodology:&#xD;
&#xD;
          -  Low back pain due to vertebral collapse or of no mechanical origin (suspected by&#xD;
             history taking and physical examination), such as neoplasm, infection or inflammatory&#xD;
             disorders,&#xD;
&#xD;
          -  Low back pain of diagnosis category 3 (low back pain radiating beyond the knee, with&#xD;
             no neurologic signs) or 4 (low back pain radiating to a precise and entire leg&#xD;
             dermatome, with or without neurologic signs), as defined by the International Paris&#xD;
             Task Force on Back Pain&#xD;
&#xD;
          -  History of inflammatory arthritis of large joints,&#xD;
&#xD;
          -  History of seizure disorders,&#xD;
&#xD;
          -  History of malignant tumour,&#xD;
&#xD;
          -  Treatment with steroidal agents (including aspirin) during the two days prior to&#xD;
             prospective inclusion, prolonged used of corticosteroids,&#xD;
&#xD;
          -  Treatment with NSAIDs or muscle relaxant or opioid analgesics within 3 days of&#xD;
             admission,&#xD;
&#xD;
          -  Psychiatric or mental diseases,&#xD;
&#xD;
          -  Immunosuppression, HIV,&#xD;
&#xD;
          -  Inclusion in another study in the past six months or previous inclusion in this study,&#xD;
&#xD;
          -  History of alcohol, drugs or narcotics abuse&#xD;
&#xD;
          -  Recent history of violent trauma,&#xD;
&#xD;
          -  Constant progressive, non mechanical pain (no relief with bed rest),&#xD;
&#xD;
          -  Thoracic pain,&#xD;
&#xD;
          -  Patient systemically unwell,&#xD;
&#xD;
          -  Unexplained weight loss,&#xD;
&#xD;
          -  Widespread neurological symptoms (including cauda equine syndrome),&#xD;
&#xD;
          -  Structural deformity&#xD;
&#xD;
          -  Fever,&#xD;
&#xD;
          -  Clinical significant renal dysfunction defined by Creatinine &gt; 1.5 UNL,&#xD;
&#xD;
          -  Clinically significant hepatic dysfunction defined by:&#xD;
&#xD;
          -  Total Bilirubin &gt; 2 UNL&#xD;
&#xD;
          -  SGOT (AST) &gt; 1.5 UNL&#xD;
&#xD;
          -  SGPT (ALAT) &gt; 1.5 UNL&#xD;
&#xD;
          -  Alkaline Phosphatase &gt; 1.5 UNL&#xD;
&#xD;
          -  Patients who have received other therapy (physiotherapy, physical manipulations,&#xD;
             invasive intervention, acupuncture therapy...) within the last 48 hours.&#xD;
&#xD;
        Exclusion criteria related to trial drugs:&#xD;
&#xD;
          -  Pregnancy, breast feeding or women of childbearing potential not using efficient&#xD;
             contraception. Patient with Intra Uterine Device should use another form of&#xD;
             contraception as the efficacy of the IUD may be reduced by ketoprofen.&#xD;
&#xD;
        Exclusion criteria related to thiocolchicoside:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to thiocolchicoside&#xD;
&#xD;
        Exclusion criteria related to ketoprofen:&#xD;
&#xD;
          -  Uncontrolled heart failure,&#xD;
&#xD;
          -  Arterial Hypertension (SBP&gt;140 mmHg or DBP &gt;90 mmHg),&#xD;
&#xD;
          -  Stroke or myocardial infarction in the past,&#xD;
&#xD;
          -  Myopathy&#xD;
&#xD;
          -  Myasthenia,&#xD;
&#xD;
          -  History of active peptic ulcer or gastrointestinal (GI) bleeding, history of gastric&#xD;
             pain with NSAIDs,&#xD;
&#xD;
          -  History of NSAID/aspirin-induced asthma,&#xD;
&#xD;
          -  Known or suspected hypersensitivity to ketoprofen.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarita MURRIETA-AGUTTES</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Egypt</country>
    <country>Guatemala</country>
    <country>Mexico</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>Sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

